Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance

Doi: https://doi.org/10.1093/jac/dkac038

Authors: Christopher A. Darlow,Nicola Farrington,Adam Johnson,Laura McEntee,Jennifer Unsworth,Ana Jimenez-Valverde,Ruwanthi Kolamunnage-Dona,Renata M. A. Da Costa,Sally Ellis,François Franceschi,

Mike Sharland,Michael Neely,Laura J. V. Piddock,Shampa Das,William Hope
Abstract: Neonatal sepsis is a serious bacterial infection of neonates, globally killing up to 680 000 babies annually. It is frequently complicated by antimicrobial resistance, particularly in low- and middle-income country (LMIC) settings with widespread resistance to the WHO’s recommended empirical regimen of ampicillin and gentamicin.